Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Boehringer Ingelheim/Pfizer's tiotropium will make a grand entrance into the chronic obstructive pulmonary disease (COPD) drug market and own approximately 44% market share by 2011. According to a new Pharmacor report entitled Chronic Obstructive Pulmonary Disease, tiotropium will attain sales of $2.1 billion in 2011 in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan).
The new drug will spur a major shift in prescribing practices. "Primary care providers will rapidly adopt tiotropium as a first-line therapy, switching existing patients from ipratropium and beta2 agonist/anticholingergic combination products," said Carilee Berg, Ph.D., analyst at Decision Resources.
COPD is a group of slowly progressive disorders characterized by airflow obstruction. This obstruction may be caused by emphysema, chronic bronchitis, or both. Generally beginning in the fourth or fifth decade of life, COPD has an insidious onset. Over time, mild shortness of breath that often goes unnoticed escalates to more serious symptoms that cannot be ignored: cough, copious and sometimes purulent sputum production, wheezing, and difficulty breathing (dyspnea). Advanced COPD typically causes significant debilitation and increases the risk of complications such as pneumonia and cardiac abnormalities.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Chronic Obstructive Pulmonary Disease is a Mosaic report.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.decisionresources.com/